New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
05:32 EDTREGN, BAYRYRegeneron Eylea injection receives EU approval for DME treatment
Regeneron Pharmaceuticals (REGN) announced that Eylea Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema, or DME. Bayer Healthcare (BAYRY) plans to launch Eylea in DME in the EU this quarter. Bayer HealthCare and Regeneron are collaborating on the global development of Eylea.
News For REGN;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
12:19 EDTBAYRYBayer downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
April 15, 2015
07:41 EDTBAYRYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 10, 2015
07:17 EDTREGNExpert very bullish on outlook for Regeneron Eylea, says RBC Capital
RBC Capital reports that a retina expert with whom it spoke was "very bullish" on the outlook for Regeneron's Eylea, not just in DME but also in wet AMD. The firm says the expert's positive outlook was sparked by recently presented Protocol T data. RBC continues to believe that Eylea could beat guidance this year, while Phase III programs could boost the stock. RBC keeps a $490 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use